Longevity Health announces 1-for-30 reverse stock split

Longevity Health (XAGE) Holdings has resolved to effect a reverse stock split of the Company’s common stock and has determined the ratio to be 1-for-30. The Company’s stockholders approved the reverse stock split and granted the Longevity board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split at the Company’s Special Meeting of Stockholders held on March 24, 2025. The reverse stock split became effective on May 12, 2025, at 9:00 a.m., Eastern Time and the Company’s common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the open of trading on May 14, 2025, under the existing ticker symbol “XAGE”. The new CUSIP number for the Company’s common stock will be 142922 129. The CUSIP number for the Company’s publicly traded warrants will not change. At the Effective Time, every 30 shares of the Company’s common stock issued and outstanding immediately prior to the Effective Time were automatically combined into one issued and outstanding share of common stock without any change in the par value per share or the total number of authorized shares. The reverse stock split reduced the number of outstanding shares of the Company’s common stock from approximately 30.1 million shares to approximately 1 million shares.